Simple Summary Most malignant tumours are highly heterogeneous at molecular and
phenotypic levels. Tumour variability poses challenges for the management of patients, as it …

Background Protein-based biomarkers are widely used in monitoring patients with
diagnosed cancer. These biomarkers however, lack specificity for cancer and have poor …

Abstract People with Li–Fraumeni syndrome (LFS) harbor a germline pathogenic variant in
the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely …

Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy
after surgery as standard‐of‐care treatment, even though only approximately 5.8% of …

Over the past decade, the detection and analysis of liquid biopsy biomarkers such as
circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have advanced …

Liquid biopsies refer to the isolation and analysis of tumor-derived biological material from
body fluids, most commonly blood, in order to provide clinically valuable information for the …

The assessment of the cancer mutational profile is crucial for patient management,
stratification, and therapeutic decisions. At present, in hematological malignancies with a …

Simple Summary The use of liquid biopsy for tumor genomic profiling to identify genomic
biomarkers for targeted therapies has revolutionized the clinical practice in oncology …

Unique bits of genetic, biological and pathological information occur in differently sized cell-
free DNA (cfDNA) populations. This is a significant discovery, but much of the phenomenon …

Background An exploratory, proof-of-concept, liquid biopsy addendum to examine
biomarkers within cell-free DNA (cfDNA) in the RELAY phase 3, randomized, double-blind …